Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran

Satar Rezaei, Maryam Bavandpour, Mohammadreza Mobinizadeh, Rajabali Daroudi · 2024

Read Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran by Satar Rezaei, Maryam Bavandpour, Mohammadreza Mobinizadeh, Rajabali Daroudi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11590557.txt.

Description

Rezaei, Bavandpour, Mobinizadeh, and Daroudi compare blood thinner options by cost effectiveness in Iran, in work from twenty twenty-four. Atrial fibrillation, a chaotic heart rhythm, raises stroke risk and needs anticoagulation. Newer drugs cost more than warfarin but need less monitoring.

Five options were compared: warfarin, apixaban, rivaroxaban, and dabigatran at two doses. A Markov model simulated patients over a lifetime from the Iranian payer perspective. Costs and health gains were weighed together. In developing health systems, such analysis decides which drugs a national formulary can afford to list for all patients.

Catalog record

CREATORSatar Rezaei, Maryam Bavandpour, Mohammadreza Mobinizadeh, Rajabali Daroudi
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE19 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11590557

Browse the full library · About the Tower of Babel